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Abstract 
Background: The actual consequence of suboptimal anticoagulation management in patients 
with non-valvular atrial fibrillation(NVAF) is unclear in the real-life practice. 
Objective: To identify the prevalence of suboptimally anticoagulated patients with NVAF, 
and compare the effectiveness and safety of antiplatelet drugs with warfarin. 
Methods: We performed a retrospective cohort study using a population-wide database 
managed by the Hong Kong Hospital Authority. Patients newly diagnosed with NVAF during 
2010-2013 were included in the analysis. Cox proportional hazards regression model with 1:1 
propensity-score-matching was used to compare the risk of ischemic stroke, intracranial 
hemorrhage(ICH), gastrointestinal bleeding(GIB), and all-cause mortality between patients 
on antiplatelet drugs and warfarin stratified by level of international normalized ratio(INR) 
control.  
Results: Among the 35,551 patients with NVAF, 30,294(85.2%) had CHA2DS2-
VASc≥2(target group for anticoagulation). Of these, 7,029(23.2%) received oral 
anticoagulants and 18,508 (61.1%) received antiplatelet drugs alone. There were 67.7% of 
warfarin users had poor INR control (time-in-therapeutic-range[2.0-3.0]<60%). Patients on 
warfarin had comparable risks of ICH(hazard ratio,1.24;95%confidence interval,0.65-2.34) 
and GIB(1.23;0.84-1.81); lower risk of ischemic stroke(0.40;0.28-0.57) and all-cause 
mortality(0.45;0.36-0.57) when compared to patients on antiplatelet drugs alone. Good INR 
control was associated with reduced risk of ischemic stroke(0.48;0.27-0.86) compared to poor 
control. Modelling analyses suggested that ~40,000 stroke cases could be potentially 
prevented per year in the Chinese population if patients were optimally treated. 
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Conclusions: Over three-quarters of high-risk patients were not anticoagulated or had poor 
INR control in this Chinese NVAF population. There is an urgent need to improve the 
optimization of anticoagulation for stroke prevention in AF patients. 
Keywords: Atrial fibrillation; oral anticoagulant; antiplatelet drugs; warfarin; Chinese  
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Introduction 
Atrial Fibrillation (AF) is the commonest sustained cardiac arrhythmia which is associated 
with a five-fold higher risk of stroke.1 Its prevalence has been increasing along with the aging 
population, and has become a significant cause of rising healthcare costs world-wide. In 
particular, Asia has a much higher AF burden compared to the Western countries. By 2050, it 
is estimated that the number of AF patients in Asia will reach 72 million, which is more than 
double of the combined figures from Europe and the United States.2  
 
Oral anticoagulation therapy (OAC) is the standard management of stroke prevention in 
patients with AF. However ,with the particular concerns of bleeding, antiplatelet drugs such 
as aspirin and clopidogrel are often perceived to be safer alternatives to OACs among the 
Asians.3 Aspirin is still recommended in the latest 2014 American Heart 
Association(AHA)/American College of Cardiology(ACC)/Heart Rhythm Society(HRS) 
guideline for stroke prevention in AF patients with CHA2DS2-VASc=1.4 Meanwhile, the US 
Food and Drug Administration is requiring additional studies for further evaluation of aspirin 
use in prevention of cardiovascular event.5 Indeed, the ‘real-world’ clinical outcome of the 
use of antiplatelet drugs for stroke prevention remains unclear, especially for the Asian 
population including Chinese.  
 
Despite the recent development of non-vitamin K antagonist oral anticoagulants (NOACs), 
warfarin remains the most commonly prescribed oral anticoagulation therapy (OAC) in AF.6 
It was estimated that about 1%-2% of the world population of developed countries were 
taking warfarin.7 The efficacy and safety on warfarin is associated with anticoagulation 
control. However, the actual quality of anticoagulation control and its impact on clinical 
outcomes among Asians are not well described in the real-life setting.  
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This study identified the suboptimally anticoagulated patients using a large population 
database in Hong Kong. Second, we studied the clinical consequence of the suboptimal 
anticoagulation of AF patients by comparing the clinical effectiveness and adverse bleeding 
events between patients on antiplatelet drugs and warfarin, based on different levels of 
anticoagulation control. 
 
Methods 
Data source 
This study used the population-wide anonymized electronic medical records of the Clinical 
Data Analysis and Reporting System (CDARS) of the Hong Kong Hospital Authority (HA), 
which is the sole public-funded healthcare provider of Hong Kong. HA is serving a 
population of over seven million through 42 hospitals, 47 Specialist Outpatient Clinics, and 
73 General Outpatient Clinics.8 Electronic patient records in HA, including demographics, 
date of registered death, date of consultation, drug dispensing records, date of hospital 
admission and discharge, diagnoses, procedures, and laboratory tests are centralized in 
CDARS and have been extensively used for epidemiological research.9-15 The high coding 
accuracy in CDARS including AF and gastrointestinal bleeding has been demonstrated in 
previous studies.10,11 Detailed descriptions of CDARS are available.10,15  
The study protocol was approved by the Institutional Review Board of the University of 
Hong Kong/Hospital Authority Hong Kong West Cluster (reference number: UW13-468). 
Informed patient consent was not required since all information used for data analysis in this 
study were anonymized. 
 
Source population 
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Patients who received their first diagnosis of AF (International Classification of Diseases 
codes, Ninth-Revision, Clinical Modification [ICD-9-CM] = 427.3) between January 1, 2010 
and December 31, 2013 in CDARS were defined as patients with newly diagnosed AF 
(Figure 1). To select for patients with non-valvular AF only, patients diagnosed with valvular 
AF, valvular heart disease or hyperthyroidism, or underwent valve replacement (ICD-9-CM; 
Supplemental Table I) within 1 year prior to their first AF occurrence were excluded. Any 
possible cases of transient AF, cardiac surgery, myocarditis, pericarditis, or pulmonary 
embolism (Supplemental Table I) within 3 months before their first AF occurrence were 
excluded. Patients aged<18 years, died during their first AF episode, or had history of 
outcome(s) were also excluded from the analysis (Figure1). 
 
Study design 
Patients were considered at high risk of stroke with the need for OAC if they had CHA2DS2-
VASc (congestive heart failure [CHF],hypertension,aged≥75y[doubled],diabetes mellitus 
[DM],aged 65-74y,prior stroke/transient ischemic attack[doubled],vascular disease, and sex 
category[female]) score≥24,16 at their first AF occurrence. The use of antiplatelet drugs 
(aspirin and/or clopidogrel) and OACs (warfarin and NOACs available in Hong Kong during 
the study period: dabigatran, rivaroxaban, and apixaban) during the first year of AF was 
examined. Patients receiving antiplatelet drugs and warfarin were included in subsequent 
analyses to study the clinical outcomes associated with suboptimal use of anticoagulation 
treatment. The start of follow-up (i.e. index date) was commenced from the date of the first 
prescription of treatment. The end of follow-up was censored by the occurrence of outcome, 
death, switching of treatment (i.e. received OAC for the antiplatelet drugs group; received an 
alternative OAC including dabigatran, rivaroxaban, and apixaban for the warfarin group), the 
end of the study period (July 31, 2014), or 90 days after discontinuation of treatment (defined 
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as >90 days of interval between prescription refills), whichever came first. The 90-day period 
was added to detect any outcomes which might have led to discontinuation of treatment.  
 
Time in therapeutic range (TTR) 
Warfarin users were further stratified into having good and poor international normalized 
ratio (INR) control based on TTR during follow-up. Poor INR control was defined as 
TTR<60%.17,18 The Rosendaal method19 was used to calculate TTR where INR was aimed at 
2.0-3.0 based on the current guidelines.4,16 This method assumes a linear relationship between 
two consecutive INR values and is well-recognized for evaluation of anticoagulation control. 
Intervals between INR measurements that were ≥8 weeks were not interpolated based on the 
formula assumptions. We excluded the INR records measured during hospitalization since 
patient could receive temporary treatment that would affect the INR values. The INR records 
in the first 28 days of warfarin were excluded from the analysis to allow time for stabilization 
of anticoagulation control. As a result, patients who had ≤28 days of follow-up were excluded 
from the analysis. To allow for fair comparison, patients in the antiplatelet drugs group who 
had ≤28 days of follow-up were also excluded. 
 
Outcomes and Data validation 
The outcomes of interest were the development of ischemic stroke, intracranial hemorrhage 
(ICH), gastrointestinal bleeding (GIB), and all-cause mortality after the commencement of 
treatment (ICD-9-CM; Supplemental Table I). A high coding accuracy for GIB (positive 
predictive value [PPV] = 100%) and AF (PPV=95%) in CDARS has been demonstrated 
previously.10 Nonetheless, we conducted further validation on the coding for ischemic stroke 
and ICH in a sample patient of this specific study cohort, where the corresponding PPVs for 
ischemic stroke and ICH were 90% and 95% respectively (Appendix I). 
 
 
10 
 
 
Statistical analysis 
Continuous variables were expressed as mean ± standard deviation whereas categorical data 
were reported as frequencies (percentages). The proportions of patients receiving antiplatelet 
drugs, OACs, and no treatment were determined. Patients on warfarin with poor INR control 
were identified.  
Cox proportional hazards regression model was used to compare the risk of the outcomes, 
between patients receiving antiplatelet drugs and warfarin with good and poor INR control, in 
terms of hazard ratios (HR) with 95% confidence intervals (CI). Absolute rates for each 
outcome were determined in all treatment groups. We estimated the number of ischemic 
strokes that could be potentially prevented per year in the Chinese AF population in mainland 
China, Hong Kong and Taiwan overall20-24 if: 1) patients on antiplatelet drugs were treated 
with warfarin; 2) patients with poor INR control achieved good INR control; based on the 
absolute risk reduction (ARR) between comparison groups (Appendix II).  
A 5% level was considered statistically significant. The ARR and number needed to treat 
(NNT) were estimated for outcomes with statistically significant results. Statistical Analysis 
System® v9.3 (SAS Institute Inc., Cary, NC) was used for conducting statistical analyses. 
Programming and analyses were performed independently by WCYL and KKCM as quality 
assurance. 
 
Propensity-score matching 
Since the choice of anticoagulation treatment is likely to be confounded by patient 
characteristics, we calculated propensity scores (PS) using logistic regression to estimate the 
likelihood to receive different treatment. The variables considered in the PS model were risk 
factors of the outcomes including age, sex, index year, CHF, hypertension, DM, myocardial 
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infarction (MI), vascular disease, transient ischemic attack/systemic embolism, bleeding, 
renal disease, and Charlson comorbidity index; recent use (≤90 days prior to index date) of 
aspirin, clopidogrel, amiodarone, statin, proton-pump inhibitors, histamine type-2 receptor 
antagonists, nonsteroidal anti-inflammatory drugs, and selective serotonin reuptake inhibitors. 
All diagnosis and medication records dated prior to individual index date were retrieved from 
CDARS for the assessment of PS variables. Patients receiving antiplatelet drugs and warfarin 
were matched at 1:1 ratio using PS-matching based on the greedy matching algorithm, which 
has been demonstrated to perform well in both actual and simulation studies.25 
 
Sensitivity analysis 
We conducted several additional analyses to test the robustness of the study results. 
Additional analyses were conducted using 180-day and 30-day permissible medication gaps 
for detecting potential discontinuation of treatment. The same duration of time was added 
after the date of discontinuation of treatment to capture any outcomes that might have led to 
treatment discontinuation. In addition, we repeated the whole analysis based on CHADS2 
(CHF, hypertension, aged≥75y, DM, prior stroke/transient ischemic attack[doubled]) score,4 
to allow for comparisons with previous studies. Gender-stratified analyses were conducted to 
test for any gender differences in the effectiveness and safety of warfarin versus antiplatelet 
drugs; and the incidence of the outcome events. 
 
Results 
Patient characteristics 
There were 41,997 patients with newly diagnosed AF between January 1, 2010 and 
December 31, 2013. Of these, 6446 patients were excluded (Figure 1). The final analysis 
included 35,551 patients with non-valvular AF where 30,294 (85.2%) patients were at high 
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risk of stroke (CHA2DS2-VASc≥2). The mean age of the patients was 76.7 ± 12.5 years and 
50.7% were female (Supplemental Table II). 
 
Underuse of anticoagulation treatment 
Among the high-risk patients with CHA2DS2-VASc≥2, 4,757 patients (15.7%) received no 
treatment, 18,508 patients (61.1%) received antiplatelet drugs alone, and 7,029 patients 
(23.2%) received OACs during the first year of AF (Figure2). Of the patients who received 
OACs, most were prescribed warfarin (n=5,048,71.8%), followed by dabigatran 
(n=2,078,29.6%), rivaroxaban (n=435,6.2%), and apixaban (n=19,0.3%). Similar results were 
found for patients with CHADS2≥2 (Figure 2; Supplemental Table III). 
 
Poor anticoagulation control 
In total, 2,276 warfarin users were included in the analysis, contributing 33,935 INR records 
(Figure1). The mean number of INR tests performed for each patient during follow-up was 
15 (standard deviation=11). There were 15,077 records (44.4%) with INR<2.0 and 3,446 
records (10.2%) with INR>3.0, respectively. Evaluation of TTR found that 1,541 patients 
(67.7%) had poor INR control. When restricted to patients with CHADS2≥2, 70.3% had poor 
INR control. 
 
Propensity-score-matching analysis  
There were 12,149 patients on antiplatelet drugs and 2,276 patients on warfarin identified for 
PS-matching (Figure 1). The mean follow-up for this cohort was 639 ± 445 days. Before PS-
matching, patients on antiplatelet drugs were older (80.3 vs.73.9y), possessed more 
comorbidities such as history of MI and higher CHA2DS2-VASc-scores as compared to those 
on warfarin (Supplemental Table IV). Based on the 1:1 matching ratio, 4,450 patients were 
 
 
13 
 
matched. The patient characteristics were balanced between treatment groups after PS-
matching (Supplemental Table IV; Supplemental Figure I).  
 
After PS-matching, the mean follow-up for the PS-matched cohort was 705 ± 448 days. 
Patients on warfarin had significantly lower risk of ischemic stroke (HR, 0.40; 95%CI, 0.28-
0.57; ARR=3.3%; NNT=31) and all-cause mortality (HR, 0.45; 95%CI, 0.36-0.57; 
ARR=6.2%; NNT=17) when compared to those on antiplatelet drugs (Table 1). No 
significant differences in the risk of ICH (HR, 1.24; 95%CI, 0.65- 2.34) and GIB (HR, 1.23; 
95%CI, 0.84-1.81) were noted between two groups. The results were not significantly 
differed by gender (Supplemental Table V). Among the patients on warfarin, those with good 
INR control were associated with reduced risk of ischemic stroke (HR, 0.48; 95%CI, 0.27-
0.86; ARR=1.8%; NNT=56), similar risk of ICH (HR, 0.89; 95%CI, 0.46-1.71), GIB (HR, 
1.08; 95%CI, 0.71-1.63), and all-cause mortality (HR, 0.89; 95%CI, 0.65-1.22) compared to 
those with poor control. Similar results were obtained in all sensitivity analyses 
(Supplemental Table VI- IX). Extrapolating our findings to the approximately 8 million 
Chinese AF patients in China, Hong Kong, and Taiwan,20-24 about 40,000 strokes could be 
potentially prevented per year among the high-risk patients on antiplatelet drugs if they were 
treated optimally with warfarin, and further about 4,000 strokes could be potentially 
prevented per year if the patients on warfarin achieved good INR control (Appendix II). 
 
Discussion 
This study highlights the considerable unmet needs in the management of Chinese AF 
patients in the ‘real-world’ clinical practice in Hong Kong, where only 23% of AF patients at 
high risk for stroke were anticoagulated in our population. Second, antiplatelet drugs were 
used in 61% of patients with AF, but its use was associated with a higher risk of ischemic 
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stroke and mortality compared to warfarin after PS-matching. Third, although warfarin was 
the most prescribed OAC (72%), two-thirds of warfarin users had poor INR control, placing 
them at higher risk of ischemic stroke than those with good INR control. The results were 
consistent for all sensitivity analyses, including the analyses using CHADS2-score as risk 
stratification for stroke; and different permissible medication gaps for detecting treatment 
discontinuation.  
 
Notably, we identified a much lower anticoagulation treatment level in this Chinese patient 
group (23%) when compared to the other areas including the United States (38.8%-71.8%), 
Europe (56.9%), Australia (65%), and the Middle East and Africa (67%).26-28 This might be 
explained by the primary concern of bleeding in the Chinese population.3 Importantly, we 
found that antiplatelet drugs, which have been commonly perceived as safer alternatives to 
OACs among the Chinese, were prescribed to more than twice the number of patients 
compared to OACs (61% vs. 23%). Indeed, higher preferences for antiplatelet drugs over 
OAC were also reported previously in China (58% vs.7%)29 and Taiwan (67% vs.15%)30. 
After taking into consideration all the patient characteristics between treatment groups, we 
found that antiplatelet drugs use was associated with comparable risks of bleeding, but 
notably a 60% higher risk of ischemic stroke when compared to warfarin. Therefore, our 
findings support that antiplatelet drugs should not be considered first line treatment for stroke 
prevention in high-risk AF patients.  
 
One of the largest RCTs that compared the use of antiplatelet drugs with warfarin in AF 
patients was the ACTIVE-W trial31 (n=6706), which showed that dual antiplatelet 
combination was inferior to warfarin in prevention of stroke with comparable bleeding events. 
However, only a small number of participants from the Chinese countries were involved in 
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this trial. Relatively small-scale RCTs among the Chinese patients were conducted by the Liu 
et al. 2014 (n=101) and Hu et al. 2008 (n=828), but the results were conflicting.21,32 While 
there are only few observational studies to compare antiplatelet drugs and warfarin, one 
retrospective cohort study of 9297 Chinese AF patients suggested that antiplatelet drugs were 
as effective as warfarin in stroke prevention, yet without assessment of any underlying 
differences in characteristics between treatment groups.29 Therefore, our study provided 
important epidemiological data concerning the use of antiplatelet drugs and warfarin in 
Chinese AF patients, where similar data are lacking. 
 
Strengths and limitations 
A key strength of this study is the utilization of the largest territory-wide clinical database in 
Hong Kong, which covers 80% of all hospital admissions.33 The inter-linkage between INR 
tests records, dispensing details and diagnosis records in hospitals as well as outpatient clinics 
facilitates comprehensive assessment of OAC use and has allowed for reliable calculations of 
TTR. While the use of OACs among AF patients has been investigated world-wide, the 
situation for Asians is inadequately explored. To our knowledge, this is the largest 
pharmacoepidemiological study conducted in Asia to inform the management of AF patients 
in a Southern Chinese population group. Importantly, we clearly identify an unmet need that 
has to be addressed with priority. 
 
Several limitations are worthy of mention. Similar to other healthcare databases, CDARS 
does not capture all the medications available over-the-counter such as aspirin. However, HA 
is the only source of publicly funded primary care in Hong Kong, of which the services and 
medications are highly subsidized (85%-98%) by the government.34 It is common for patients 
with chronic illness requiring long-term medications, such as AF, to attend outpatient clinics 
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of the HA for ongoing treatment care rather than obtaining full-cost medications from 
elsewhere.34 Therefore, the impact of uncaptured prescriptions is anticipated to be minimal. 
The estimated number of potentially preventable stroke cases in the Chinese population was 
based on the treatment characteristics in this Chinese cohort of Hong Kong. Therefore, it may 
not be generalizable to the whole Chinese population. However, since considerable underuse 
of OACs was reported in other Chinese populations in the mainland China and Taiwan,21,28-30 
our extrapolation is likely to be conservative. Given the significant underuse of warfarin, and 
the small proportion of patients with good INR control, this study might have insufficient 
power to detect a statistical significance in the analyses for good INR control. Finally, as the 
volume of NOACs increases, there will be opportunities for meaningful comparison with 
warfarin and antiplatelet drugs as well as long-term safety surveillance of NOACs.  
 
Conclusion 
In this cohort, over three-quarters of high-risk patients with non-valvular AF were either not 
protected by anticoagulation or had poor INR control. Compared to patients prescribed 
warfarin, patients on antiplatelet drugs were not statistically associated with reduced risk of 
bleeding, but higher risk of ischemic stroke and all-cause mortality. It is important to study 
the reasons for the underutilization of anticoagulation therapy. Measures are urgently needed 
to raise awareness and improve the underutilization and optimization of anticoagulation in 
AF patients, especially in the Chinese population.  
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Figure 1.Flow of patients 
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Figure 2.Distribution of the use of antithrombotic therapy stratified by risk of stroke 
  
 
 
23 
 
Table 1.Outcome events among patients receiving antiplatelet drugs and warfarin. 
  
 
Overall cohort PS-matched cohort 
  N 
No. of 
events/absolute 
risk/incidence† 
Warfarin vs. 
Antiplatelet drugs, 
HR(95%CI) 
Good vs. Poor 
INR control, 
HR(95%CI) 
N 
No. of 
events/absolute 
risk/incidence† 
Warfarin vs. 
Antiplatelet drugs, 
HR(95%CI) 
Good vs. Poor 
INR control, 
HR(95%CI) 
Ischemic stroke 
 
 
      
Antiplatelet drugs 12149 761/6.3/3.7 Reference - 2225 144/6.5/3.6 Reference - 
Warfarin 2276 73/3.2/1.6 0.42 (0.33, 0.53)* - 2225 72/3.2/1.6 0.40 (0.28, 0.57)* - 
    Poor INR control 1541 59/3.8/1.9 0.51 (0.39, 0.67)* Reference 1510 58/3.8/1.9 0.41 (0.27, 0.62)* Reference 
    Good INR control 735 14/1.9/0.9 0.24 (0.14, 0.41)* 0.47 (0.26, 0.84)* 715 14/2.0/0.9 0.37 (0.18, 0.73)* 0.48 (0.27, 0.86)* 
  
 
 
      
Intracranial hemorrhage 
 
 
      
Antiplatelet drugs 12149 178/1.5/0.9 Reference - 2225 24/1.1/0.6 Reference - 
Warfarin 2276 42/1.8/0.9 1.03 (0.74, 1.44) - 2225 42/1.9/0.9 1.24 (0.65, 2.34) - 
    Poor INR control 1541 29/1.9/0.9 1.07 (0.72, 1.59) Reference 1510 29/1.9/1.0 1.07 (0.52, 2.22) Reference 
    Good INR control 735 13/1.8/0.8 0.95 (0.54, 1.66) 0.88 (0.46, 1.69) 715 13/1.8/0.8 2.00 (0.50, 8.00) 0.89 (0.46, 1.71) 
  
 
 
      
Gastrointestinal bleeding 
 
 
      
Antiplatelet drugs 12149 495/4.1/2.4 Reference - 2225 74/3.3/1.9 Reference - 
Warfarin 2276 101/4.4/2.2 0.89 (0.72, 1.10) - 2225 99/4.4/2.2 1.23 (0.84, 1.81) - 
    Poor INR control 1541 65/4.2/2.1 0.86 (0.67, 1.12) Reference 1510 64/4.2/2.1 1.41 (0.86, 2.31) Reference 
    Good INR control 735 36/4.9/2.3 0.94 (0.67, 1.32) 1.08 (0.72, 1.63) 715 35/4.9/2.3 1.00 (0.54, 1.86) 1.08 (0.71, 1.63) 
          
All-cause mortality 
 
 
      
Antiplatelet drugs 12149 2533/20.8/12.3 Reference - 2225 315/14.2/7.9 Reference - 
Warfarin 2276 181/8.0/3.9 0.32 (0.28, 0.37)* - 2225 177/8.0/3.9 0.45 (0.36, 0.57)* - 
    Poor INR control 1541 125/8.1/4.0 0.33 (0.28, 0.40)* Reference 1510 122/8.1/4.0 0.43 (0.32, 0.57)* Reference 
    Good INR control 735 56/7.6/3.5 0.30 (0.23, 0.39)* 0.88 (0.64, 1.20) 715 55/7.7/3.6 0.49 (0.34, 0.73)* 0.89 (0.65, 1.22) 
Abbreviations: PS, propensity score; HR, hazard ratio; CI, confidence interval; INR, international normalized ratio. Poor INR control, time-in-therapeutic-range<60%; Good 
INR control, time-in-therapeutic-range≥60%.  
*P-value<0.05. †absolute risk per 100 patients; incidence per 100 patient-years. 
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Appendix I. Data validation  
To validate the coding accuracy for ischemic stroke and intracranial hemorrhage (ICH) in the Clinical Data 
Analysis and Reporting System database (CDARS), original medical records of the patients from the Hong 
Kong West Cluster (HKWC), which is one of the seven hospital clusters of the Hospital Authority, were 
extracted for data validation. The HKWC has a population of over half a million, representing 8% of the total 
population of Hong Kong.1 It manages seven hospitals, one specialist rehabilitation center, and six general 
outpatient clinics.1,2 The age and sex characteristics of the people in the HKWC are similar to that of the overall 
Hong Kong population.3 The diagnoses of ischemic stroke and ICH were ascertained by radiology, 
computerized tomography or magnetic resonance imaging of the brain, or documentation of the disease in 
medical chart. The corresponding positive predictive values (PPV) were calculated. 
In this study, 14425 patients were included in the analysis for the risk of ischemic stroke and ICH (before 
propensity-score matching). Of these, 1404 patients (10%) were from the HKWC. All patients who had 
ischemic stroke (n=71) and ICH (n=19) were selected from the HKWC for validation. The corresponding PPVs 
for ischemic stroke and ICH were 90% (64 out of 71) and 95% (18 out of 19) respectively. 
 
References 
1. Hospital Authority. Clinical Services Plan for the Hong Kong West Cluster. 2013; 
http://www.ha.org.hk/upload/publication_44/453.pdf. Accessed 23rd July 2015. 
2. The Hospital Authority. Clusters, Hospitals & Institutions. 
http://www.ha.org.hk/visitor/ha_visitor_text_index.asp?Content_ID=10036&Lang=ENG&Dimension=100&Par
ent_ID=10004&Ver=TEXT. Accessed 23rd July 2015. 
3. Census and Statistics Department HKSAR. Population and Household Statistics Analysed by District Council 
District 2013. 2013; http://www.statistics.gov.hk/pub/B11303012013AN13B0100.pdf. Accessed 23rd July 2015. 
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Appendix II. Modelling analysis 
We extrapolated our findings to the whole Chinese population in mainland China, Hong Kong and Taiwan to 
estimate the number of ischemic stroke cases that could be potentially prevented per year by the optimal use of 
anticoagulation treatment in the high-risk patients with atrial fibrillation (AF) over the study period (1st January 
2010 – 31st July 2014): 
 
Scenario 1: if patients on antiplatelet drugs were optimally treated with warfarin. 
Method: [Total number of Chinese population with AF] x [proportion of high-risk patients] x [proportion of 
patients on antiplatelet drugs] ÷ [number needed to treat; calculated as 1/absolute risk reduction (event rate on 
antiplatelet drugs – event rate on warfarin)] ÷ [length of study period]; 
Scenario 2: if patients with poor INR control achieved good INR control. 
Method: [Total number of Chinese population with AF] x [proportion of high-risk patients] x [proportion of 
patients on warfarin] x [proportion of patients with poor INR control] ÷ [number needed to treat; calculated as 
1/absolute risk reduction (event rate on poor INR control – event rate on good INR control)] ÷ [length of study 
period]. 
 
The estimated number of patients with AF in the Chinese population was 8 million.1-5 Therefore, based on the 
findings in our study, there were 8 million x 85% x 61% ÷ [1/ (6.5%-3.2%)] ÷ 3.6 years = approx. 40000 
ischemic stroke cases that could be potentially prevented per year among the patients on antiplatelet drugs if 
they were optimally treated with warfarin; and 8 million x 85% x 17% x 68% ÷ [1/(3.8%-2.0%)] ÷ 3.6 years   = 
approx. 4000 ischemic stroke cases that could be potentially prevented per year if patients on warfarin had good 
INR control. 
 
References 
1. Tse HF, Wang YJ, Ai-Abdullah MA, et al. Stroke prevention in atrial fibrillation-An Asian stroke perspective. 
Heart rhythm: the official journal of the Heart Rhythm Society. Jul 2013;10(7):1082-1088. 
2. Hu D, Sun Y. Epidemiology, risk factors for stroke, and management of atrial fibrillation in China. Journal of 
the American College of Cardiology. Sep 2 2008;52(10):865-868. 
3. Census and Statistics Department, The Government of the Hong Kong Special Administrative Region. Hong 
Kong Statistics (Population Estimates). 2015; 
http://www.censtatd.gov.hk/hkstat/sub/sp150.jsp?tableID=001&ID=0&productType=8. Accessed May 21, 2015, 
2015. 
4. Lip GYH, Brechin CM, Lane DA. The Global Burden of Atrial Fibrillation and Stroke A Systematic Review 
of the Epidemiology of Atrial Fibrillation in Regions Outside North America and Europe. Chest. Dec 
2012;142(6):1489-1498. 
5. Ministry of the Interior, Republic of China (Taiwan). Number of Villages, Neighborhoods, Households and 
Resident Population. 2015; http://sowf.moi.gov.tw/stat/month/elist.htm. Accessed 21st May 2015. 
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Figure I. Distribution of propensity scores between treatment groups. 
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Table I. International Classification of Diseases codes, Ninth Revision, Clinical 
Modification (ICD-9-CM) codes used in the study. 
ICD-9-CM codes Descriptions 
Atrial fibrillation 
427.3 Atrial fibrillation and flutter 
  Valvular heart diseases/replacement or hyperthyroidism 
242 Thyrotoxicosis with or without goitre 
394.0 Mitral stenosis 
  Procedure codes 
35.20 Open and other replacement of unspecified heart valve 
35.22 Open and other replacement of aortic valve 
35.24 Open and other replacement of mitral valve 
35.26 Open and other replacement of pulmonary valve 
35.28 Open and other replacement of tricuspid valve 
  Transient atrial fibrillation 
Cardiac surgery (procedure codes) 
00.5 Other cardiovascular procedures 
35 Operations on valves and septa of heart 
36 Operations on vessels of heart 
37 Other operations on heart and pericardium 
  Pericarditis 
391 Rheumatic fever with heart involvement 
393 Chronic rheumatic pericarditis 
420 Acute pericarditis 
423.2 Constrictive pericarditis 
036.41 Meningococcal pericarditis 
074.21 Coxsackie pericarditis 
093.81 Syphilitic pericarditis 
098.83 Gonococcal pericarditis 
  Myocarditis 
130.3 
 391.2 Acute rheumatic myocarditis 
398.0 Rheumatic myocarditis 
422 Acute myocarditis 
429.0 Myocarditis, unspecified 
032.82 Diphtheritic myocarditis 
036.43 Meningococcal myocarditis 
074.23 Coxsackie myocarditis 
093.82 Syphilitic myocarditis 
  Pulmonary embolism 
415.1 Pulmonary embolism and infarction 
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Table I. International Classification of Diseases codes, Ninth Revision, Clinical 
Modification (ICD-9-CM) codes used in the study [continued]. 
ICD-9-CM codes Descriptions 
CHADS2 and CHA2DS2-VASc scores 
Congestive Heart Failure 
398.91 Rheumatic heart failure (congestive)  
402.01 Malignant hypertensive heart disease with heart failure 
402.11 Benign hypertensive heart disease with heart failure 
402.91 Unspecified hypertensive heart disease with heart failure 
404.01 
Hypertensive heart and chronic kidney disease, malignant, with heart failure 
and with chronic kidney disease stage I through stage IV, or unspecified 
404.03 
Hypertensive heart and chronic kidney disease, malignant, with heart failure 
and with chronic kidney disease stage V or end stage renal disease 
404.11 
Hypertensive heart and chronic kidney disease, benign, with heart failure and 
with chronic kidney disease stage I through stage IV, or unspecified 
404.13 
Hypertensive heart and chronic kidney disease, benign, with heart failure and 
chronic kidney disease stage V or end stage renal disease  
404.91 
Hypertensive heart and chronic kidney disease, unspecified, with heart 
failure and with chronic kidney disease stage I through stage IV, or 
unspecified  
404.93 
Hypertensive heart and chronic kidney disease, unspecified, with heart 
failure and chronic kidney disease stage V or end stage renal disease 
428 Heart failure 
  Hypertension 
401 Essential hypertension 
402 Hypertensive heart disease  
403 Hypertensive chronic kidney disease  
404 Hypertensive heart and chronic kidney disease  
405 Secondary hypertension 
437.2 Hypertensive encephalopathy 
  Diabetes 
 250 Diabetes mellitus 
  Ischaemic stroke 
433.01 Occlusion and stenosis of basilar artery with cerebral infarction   
433.11 Occlusion and stenosis of carotid artery with cerebral infarction   
433.21 Occlusion and stenosis of vertebral artery with cerebral infarction   
433.31 
Occlusion and stenosis of multiple and bilateral precerebral arteries with 
cerebral infarction   
433.81 
Occlusion and stenosis of other specified precerebral artery with cerebral 
infarction 
433.91 
Occlusion and stenosis of unspecified precerebral artery with cerebral 
infarction 
434 Occlusion of cerebral arteries   
436 Acute, but ill-defined, cerebrovascular disease 
437.0 Cerebral atherosclerosis   
437.1 Other generalized ischemic cerebrovascular disease   
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Table I. International Classification of Diseases codes, Ninth Revision, Clinical 
Modification (ICD-9-CM) codes used in the study [continued]. 
ICD-9-CM codes Descriptions 
Transient ischaemic attack 
435 Transient cerebral ischemia   
  Systemic embolism 
444  Arterial embolism and thrombosis 
445 Atheroembolism 
  
Vascular disease 
410-414 Ischemic heart disease 
443.8 Other specified peripheral vascular diseases 
443.9 Peripheral vascular disease, unspecified 
  
Myocardial infarction 
410 Acute myocardial infarction 
  Intracranial haemorrhage 
430 Subarachnoid haemorrhage 
431 Intracerebral haemorrhage 
432 Other and unspecified intracranial haemorrhage 
  Gastrointestinal bleeding 
531.0 Acute gastric ulcer with hemorrhage 
531.2 
Acute gastric ulcer with hemorrhage and perforation, without mention of 
obstruction 
531.4 Chronic or unspecified gastric ulcer with hemorrhage 
531.6 Chronic or unspecified gastric ulcer with hemorrhage and perforation 
532.0 Acute duodenal ulcer with hemorrhage 
532.2 Acute duodenal ulcer with hemorrhage and perforation 
532.4 Chronic or unspecified duodenal ulcer with hemorrhage 
532.6 Chronic or unspecified duodenal ulcer with hemorrhage and perforation 
533.0 Acute peptic ulcer of unspecified site with hemorrhage 
533.2 Acute peptic ulcer of unspecified site with hemorrhage and perforation 
533.4 Chronic or unspecified peptic ulcer of unspecified site with hemorrhage 
533.6 
Chronic or unspecified peptic ulcer of unspecified site with hemorrhage and 
perforation 
534.0 Acute gastrojejunal ulcer with hemorrhage 
534.2 
Acute gastrojejunal ulcer with hemorrhage and perforation, without mention 
of obstruction 
534.4 Chronic or unspecified gastrojejunal ulcer with hemorrhage 
534.6 Chronic or unspecified gastrojejunal ulcer with hemorrhage and perforation 
535.01 Acute gastritis, with hemorrhage 
535.11 Atrophic gastritis, with hemorrhage 
535.21 Gastric mucosal hypertrophy, with hemorrhage 
535.31 Alcoholic gastritis, with hemorrhage 
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Table I. International Classification of Diseases codes, Ninth Revision, Clinical 
Modification (ICD-9-CM) codes used in the study [continued]. 
ICD-9-CM codes Descriptions 
Gastrointestinal bleeding [continued] 
535.41 Other specified gastritis, with hemorrhage 
535.51 Unspecified gastritis and gastroduodenitis, with hemorrhage 
535.61 Duodenitis, with hemorrhage 
535.71 Eosinophilic gastritis, with hemorrhage  
562.02 Diverticulosis of small intestine with hemorrhage 
562.03 Diverticulitis of small intestine with haemorrhage 
562.12 Diverticulosis of colon with haemorrhage 
562.13 Diverticulitis of colon with haemorrhage 
569.3 Hemorrhage of rectum and anus 
569.85 Angiodysplasia of intestine with haemorrhage 
569.86 Dieulafoy lesion (hemorrhagic) of intestine 
578.0 Hematemesis 
578.1 Melena 
578.9 Hemorrhage of gastrointestinal tract, unspecified 
  Other bleeding 
423.0 Hemopericardium 
459.0 Haemorrhage NOS 
593.81 Vascular disorders of kidney 
599.7 Haematuria 
623.8 Other specified noninflammatory disorders of vagina 
626.2 Excessive menstruation 
626.6 Metrorrhagia 
719.1 Hemarthrosis 
784.7 Epistaxis 
784.8 Haemorrhage from throat 
786.3 Haemoptysis 
  Renal disease  
403 Hypertensive chronic kidney disease 
404 Hypertensive heart and chronic kidney disease 
580 Acute glomerulonephritis 
581 Nephrotic syndrome 
582 Chronic glomerulonephritis 
583 Nephritis and nephropathy not specified as acute or chronic 
584 Acute kidney failure 
585 Chronic kidney disease (ckd) 
586 Renal failure unspecified 
590.0 Chronic pyelonephritis 
753.1 Cystic kidney disease 
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Table I. International Classification of Diseases codes, Ninth Revision, Clinical 
Modification (ICD-9-CM) codes used in the study [continued]. 
ICD-9-CM codes Descriptions 
Charlson comorbidity index 
Myocardial infarction 
410 Acute myocardial infarction 
  Congestive Heart Failure 
398.91 Rheumatic heart failure (congestive)  
402.01 Malignant hypertensive heart disease with heart failure 
402.11 Benign hypertensive heart disease with heart failure 
402.91 Unspecified hypertensive heart disease with heart failure 
404.01 Hypertensive heart and chronic kidney disease, malignant, with heart 
failure and with chronic kidney disease stage I through stage IV, or 
unspecified 
404.03 Hypertensive heart and chronic kidney disease, malignant, with heart 
failure and with chronic kidney disease stage V or end stage renal disease 
404.11 Hypertensive heart and chronic kidney disease, benign, with heart failure 
and with chronic kidney disease stage I through stage IV, or unspecified 
404.13 Hypertensive heart and chronic kidney disease, benign, with heart failure 
and chronic kidney disease stage V or end stage renal disease  
404.91 Hypertensive heart and chronic kidney disease, unspecified, with heart 
failure and with chronic kidney disease stage I through stage IV, or 
unspecified  
404.93 Hypertensive heart and chronic kidney disease, unspecified, with heart 
failure and chronic kidney disease stage V or end stage renal disease 
428 Heart failure 
  
Peripheral vascular disease 
441 Aortic aneurysm and dissection 
443.9 Peripheral vascular disease, unspecified 
785.4 Gangrene 
V43.4 Blood vessel replaced by other means 
  
Cerebrovascular disease 
430-438 Cerebrovascular disease 
  
Chronic obstructive pulmonary disease 
490-496 Chronic Obstructive Pulmonary Disease and Allied Conditions 
500 Coal workers' pneumoconiosis 
501 Asbestosis 
502 Pneumoconiosis due to other silica or silicates 
503 Pneumoconiosis due to other inorganic dust 
504 Pneumonopathy due to inhalation of other dust 
505 Pneumoconiosis, unspecified 
506.4 Respiratory conditions due to chemical fumes and vapors 
  
Dementia 
290 Dementias 
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Table I. International Classification of Diseases codes, Ninth Revision, Clinical 
Modification (ICD-9-CM) codes used in the study [continued]. 
ICD-9-CM codes Descriptions 
Charlson comorbidity index [continued] 
Paralysis 
342 Hemiplegia and hemiparesis 
344.1 Paraplegia 
  
Diabetes without chronic complication 
250.0 Diabetes mellitus without mention of complication 
250.1 Diabetes with ketoacidosis 
250.2 Diabetes with hyperosmolarity 
250.3 Diabetes with other coma 
250.7 Diabetes with peripheral circulatory disorders 
  
Diabetes with chronic complication 
250.4 Diabetes with renal manifestations 
250.5 Diabetes with ophthalmic manifestations 
250.6 Diabetes with neurological manifestations 
  
Chronic renal failure 
582 Chronic glomerulonephritis 
583.0 Nephritis and nephropathy, not specified as acute or chronic, with lesion of 
proliferative glomerulonephritis 
583.1 Nephritis and nephropathy, not specified as acute or chronic, with lesion of 
membranous glomerulonephritis 
583.2 Nephritis and nephropathy, not specified as acute or chronic, with lesion of 
membranoproliferative glomerulonephritis 
583.4 Nephritis and nephropathy, not specified as acute or chronic, with lesion of 
rapidly progressive glomerulonephritis 
583.6 Nephritis and nephropathy, not specified as acute or chronic, with lesion of 
renal cortical necrosis 
583.7 Nephritis and nephropathy, not specified as acute or chronic, with lesion of 
renal medullary necrosis 
585 Chronic kidney disease (ckd) 
586 Renal failure, unspecified 
588 Disorders resulting from impaired renal function 
  
Various cirrhodites 
571.2 Alcoholic cirrhosis of liver 
571.4 Chronic hepatitis 
571.5 Cirrhosis of liver without mention of alcohol  
571.6 Biliary cirrhosis 
  
Moderate-severe liver disease 
456.0 Esophageal varices with bleeding 
456.1 Esophageal varices without bleeding 
456.2 Esophageal varices in diseases classified elsewhere 
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Table I. International Classification of Diseases codes, Ninth Revision, Clinical 
Modification (ICD-9-CM) codes used in the study [continued]. 
ICD-9-CM codes Descriptions 
Charlson comorbidity index [continued] 
Moderate-severe liver disease [continued] 
572.2 Hepatic encephalopathy 
572.3 Portal hypertension 
572.4 Hepatorenal syndrome 
572.8 Other sequelae of chronic liver disease 
  
Ulcers 
531 Gastric ulcer 
532 Duodenal ulcer 
533 Peptic ulcer site unspecified 
534 Gastrojejunal ulcer 
 
Rheumatoid arthritis and other inflammatory polyarthropathies 
710.0 Systemic lupus erythematosus 
710.1 Systemic sclerosis 
710.4 Polymyositis 
714.0 Rheumatoid arthritis 
714.1 Felty's syndrome 
714.2 Other rheumatoid arthritis with visceral or systemic involvement 
714.81 Rheumatoid lung 
725 Polymyalgia rheumatica 
  
Acquired Immune Deficiency Syndrome 
042 Human immunodeficiency virus [HIV] disease 
  
Malignancy  
140-149 Malignant neoplasm of lip, oral cavity, and pharynx 
150-159 Malignant neoplasm of digestive organs and peritoneum 
160-165 Malignant neoplasm of respiratory and intrathoracic organs 
170-172, 174-176 Malignant neoplasm of bone, connective tissue, and breast 
179-189 Malignant neoplasm of genitourinary organs 
190-195 Malignant neoplasm of other sites 
200-208 Malignant neoplasm of lymphatic and hematopoietic tissue 
  
Metastatic solid tumour 
196 Secondary and unspecified malignant neoplasm of lymph nodes 
197 Secondary malignant neoplasm of respiratory and digestive systems 
198 Secondary malignant neoplasm of other specified sites 
199 Malignant neoplasm without specification of site 
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Table II. Baseline characteristics. 
Characteristics Overall (%) 
Total 35 551 
Age (years), mean ± SD 76.7 ± 12.5 
Age ≥65 29 248 (82.3) 
Age ≥75  22 492 (63.3) 
Sex (Female) 18 015 (50.7) 
Baseline medical conditions 
 
  Congestive heart failure 9287 (26.1) 
  Diabetes 8067 (22.7) 
  Hypertension 18 633 (52.4) 
  Myocardial infarction 2819 (7.9) 
  Vascular disease 8613 (24.2) 
  Prior ischaemic stroke/TIA/SE 7392 (20.8) 
  Prior bleeding 7412 (20.8) 
    Intracranial bleeding 1334 (3.8) 
    Gastrointestinal bleeding 3836 (10.8) 
    Others* 3063 (8.6) 
  Renal disease 4577 (12.9) 
  CHA2DS2-VASc score, mean ± SD 3.6 ± 1.9 
    0 1901 (5.3) 
    1 3356 (9.4) 
    2 5001 (14.1) 
    ≥3 25 293 (71.1) 
  CHADS2 score, mean ± SD 2.1 ± 1.5 
    0 5462 (15.4) 
    1 8602 (24.2) 
    2 8767 (24.7) 
    ≥3 12 720 (35.8) 
  Charlson comorbidity index, mean ± SD 1.8 ± 1.9 
    0-3 30 598 (86.1) 
    4-5 3138 (8.8) 
    6-7 913 (2.6) 
    ≥8 902 (2.5) 
Recent use of medications 
 
  Aspirin 19018 (53.5) 
  Clopidogrel 1808 (5.1) 
  Amiodarone 4714 (13.3) 
  Statin 9655 (27.2) 
  Proton-pump inhibitor 7535 (21.2) 
  Histamine type-2 receptor antagonist 15918 (44.8) 
  NSAIDs 2374 (6.7) 
  SSRIs 935 (2.6) 
Abbreviations: SD, standard deviation; TIA, transient ischaemic attack; SE, systemic 
embolism; NSAIDs, nonsteroidal anti-inflammatory drugs; SSRIs, selective serotonin 
reuptake inhibitors. 
*includes epistaxis, haematuria, haemarthrosis, haemorrhage from kidney, throat, and 
vagina, hemopericardium, and haemoptysis. 
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Table III. Distribution of the use of oral anticoagulants during the first year of atrial fibrillation. 
 
Overall Low or moderate risk High risk 
Oral anticoagulants, no. of patients (%)* 
All users 
(n=8398) 
CHADS2 <2 
(n=3356) 
CHA2DS2-VASc <2 
(n=1369) 
CHADS2 ≥ 2 
(n=5042) 
CHA2DS2-VASc ≥ 2 
(n=7029) 
Warfarin 6151 (73.2) 2514 (74.9) 1103 (80.6) 3637 (72.1) 5048 (71.8) 
NOACs 2789 (33.2) 1032 (30.8) 341 (24.9) 1757 (34.8) 2448 (34.8) 
      Apixaban 23 (0.3) 12 (0.4) 4 (0.3) 11 (0.2) 19 (0.3) 
      Dabigatran 2362 (28.1) 859 (25.6) 284 (20.7) 1503 (29.8) 2078 (29.6) 
      Rivaroxaban 493 (5.9) 197 (5.9) 58 (4.2) 296 (5.9) 435 (6.2) 
Abbreviations: NOACs, non-vitamin K antagonist oral anticoagulants. 
*included patients who were exposed to more than one type of oral anticoagulant during their first year of atrial fibrillation (hence figures do not add to 
100%). 
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Table IV. Characteristics of patients before and after propensity score matching. 
Characteristics Before PS matching After PS matching 
 
Antiplatelet drugs 
(n=12 149) 
Warfarin 
(n=2276) 
Standardized 
difference* 
Antiplatelet drugs 
(n=2225) 
Warfarin 
(n=2225) 
Standardized 
difference* 
Age (years), mean ± SD 80.3 ± 9.2 73.9 ± 9.7 -0.67 74.0 ± 10.5 74.3 ± 9.3 0.03 
Age >=65 11 418 (94.0) 1892 (83.1) -0.35 1826 (82.1) 1881 (84.5) 0.07 
Age >=75 9237 (76.0) 1217 (53.5) -0.49 1139 (51.2) 1213 (54.5) 0.07 
Sex (Female) 6875 (56.6) 1204 (52.9) -0.07 1189 (53.4) 1185 (53.3) -0.004 
Baseline medical conditions 
   
   
  Congestive heart failure 4006 (33.0) 856 (37.6) 0.10 794 (35.7) 827 (37.2) 0.03 
  Diabetes 2902 (23.9) 635 (27.9) 0.09 573 (25.8) 624 (28.0) 0.05 
  Hypertension 6875 (56.6) 1251 (55.0) -0.03 1248 (56.1) 1230 (55.3) -0.02 
  Myocardial infarction 1355 (11.2) 149 (6.5) -0.16 140 (6.3) 148 (6.7) 0.01 
  Vascular disease 3818 (31.4) 607 (26.7) -0.10 575 (25.8) 598 (26.9) 0.02 
  Prior transient ischemic attack or systemic embolism 253 (2.1) 174 (7.6) 0.26 120 (5.4) 142 (6.4) 0.04 
  Prior bleeding 998 (8.2) 184 (8.1) -0.005 174 (7.8) 178 (8.0) 0.01 
  Renal disease 1704 (14.0) 221 (9.7) -0.13 195 (8.8) 219 (9.8) 0.04 
  CHA2DS2-VASc score, mean ± SD 3.8 ± 1.3 3.5 ± 1.3 -0.18 3.4 ± 1.3 3.5 ± 1.3 0.09 
    2 2405 (19.8) 588 (25.8) 0.14 707 (31.8) 568 (25.5) -0.14 
    3 3287 (27.1) 657 (28.9) 0.04 599 (26.9) 644 (28.9) 0.05 
    ≥4 6457 (53.1) 1031 (45.3) -0.16 919 (41.3) 1013 (45.5) 0.09 
  CHADS2 score, mean ± SD 1.9 ± 1.0 1.9 ± 1.1 -0.04 1.8 ± 1.1 1.9 ± 1.0 0.08 
    0-1 4515 (37.2) 891 (39.1) 0.04 988 (44.4) 881 (39.6) -0.10 
    2 4229 (34.8) 795 (34.9) 0.003 694 (31.2) 777 (34.9) 0.08 
    3 2578 (21.2) 424 (18.6) -0.06 407 (18.3) 412 (18.5) 0.01 
    ≥4 827 (6.8) 166 (7.3) 0.02 136 (6.1) 155 (7.0) 0.03 
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Table IV. Characteristics of patients before and after propensity score matching [continued]. 
Characteristics Before PS matching After PS matching 
 
Antiplatelet drugs 
(n=12 149) 
Warfarin 
(n=2276) 
Standardized 
difference* 
Antiplatelet drugs 
(n=2225) 
Warfarin 
(n=2225) 
Standardized 
difference* 
Charlson comorbidity index, mean ± SD 1.5 ± 1.8 1.3 ± 1.4 -0.15 1.2 ± 1.3 1.3 ± 1.3 0.05 
    0-3 10 796 (88.9) 2116 (93.0) 0.14 2080 (93.5) 2068 (92.9) -0.02 
    4-5 891 (7.3) 123 (5.4) -0.08 117 (5.3) 122 (5.5) 0.01 
    6-7 263 (2.2) 28 (1.2) -0.07 24 (1.1) 28 (1.3) 0.02 
    ≥8 199 (1.6) 9 (0.4) -0.12 4 (0.2) 7 (0.3) 0.03 
Recent use of medications 
   
   
  Aspirin 7870 (64.8) 1259 (55.3) -0.19 1222 (54.9) 1239 (55.7) 0.02 
  Clopidogrel 825 (6.8) 113 (5.0) -0.08 105 (4.7) 112 (5.0) 0.01 
  Amiodarone 1631 (13.4) 251 (11.0) -0.07 229 (10.3) 245 (11.0) 0.02 
  Statin 3033 (25.0) 768 (33.7) 0.19 727 (32.7) 741 (33.3) 0.01 
  Proton-pump inhibitor 2361 (19.4) 362 (15.9) -0.09 325 (14.6) 357 (16.0) 0.04 
  Histamine type-2 receptor antagonist 5817 (47.9) 1048 (46.0) -0.04 1001 (45.0) 1027 (46.2) 0.02 
  NSAIDs 806 (6.6) 132 (5.8) -0.03 145 (6.5) 128 (5.8) -0.03 
  SSRIs 247 (2.0) 37 (1.6) -0.03 36 (1.6) 37 (1.7) 0.004 
Anticoagulation control (for warfarin users only) 
   
   
  Total number of INR tests   33 935   33 174  
  Number of INR tests performed for each patient,  mean ± SD  15 ± 11   15 ± 11  
  Time in therapeutic range, mean ± SD  44.6 ± 28.8%   44.4 ± 28.8%  
      <30% 
 
754 (33.1) 
 
 742 (33.3)  
      30-40% 
 
254 (11.2) 
 
 249 (11.2)  
      40-50% 
 
280 (12.3) 
 
 275 (12.4)  
      50-60% 
 
253 (11.1) 
 
 244 (11.0)  
      60-70% 
 
244 (10.7) 
 
 241 (10.8)  
      ≥70% 
 
491 (21.6) 
 
 474 (21.3)  
Abbreviations: PS, propensity score; SD, standard deviation; NSAIDs, nonsteroidal anti-inflammatory drugs; SSRIs, selective serotonin reuptake inhibitors; INR, international normalized 
ratio. 
*Standardized difference is the mean difference divided by the pooled standard deviation. 
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Table V. Gender-stratified analyses. 
  Overall cohort PS-matched cohort 
  Male Female  
Male Female 
 
 
N 
No. of cases 
(incidence*) 
N 
No. of cases 
(incidence*) 
p-value for 
gender 
difference† 
N 
No. of cases 
(incidence*) 
N 
No. of cases 
(incidence*) 
p-value for 
gender 
difference† 
Ischemic stroke 
          
Overall 6346 306 (2.8) 8079 528 (3.7) <0.001 2076 96 (2.4) 2374 120 (2.6) 0.56 
Antiplatelet drugs 5274 267 (3.1) 6875 494 (4.2) <0.001 1036 58 (3.2) 1189 86 (3.9) 0.22 
Warfarin 1072 39 (1.8) 1204 34 (1.4) 0.32 1040 38 (1.8) 1185 34 (1.4) 0.35 
Warfarin vs. Antiplatelet drugs, 
HR (95% CI) 
0.57 (0.41, 0.80) 0.33 (0.23, 0.47) 0.03 0.52 (0.25, 1.09) 0.29 (0.14, 0.61) 0.27 
            Intracranial hemorrhage 
          
Overall 6346 102 (0.9) 8079 118 (0.8) 0.38 2076 29 (0.7) 2374 37 (0.8) 0.69 
Antiplatelet drugs 5274 83 (1.0) 6875 95 (0.8) 0.27 1036 10 (0.6) 1189 14 (0.6) 0.71 
Warfarin 1072 19 (0.9) 1204 23 (0.9) 0.76 1040 19 (0.9) 1185 23 (1.0) 0.79 
Warfarin vs. Antiplatelet drugs, 
HR (95% CI) 
0.89 (0.54, 1.47) 1.16 (0.74, 1.83) 0.44 1.00 (0.20, 4.96) 1.40 (0.44, 4.41) 0.74 
  
          
Gastrointestinal bleeding 
Overall 6346 255 (2.3) 8079 341 (2.4) 0.74 2076 78 (2.0) 2374 95 (2.1) 0.73 
Antiplatelet drugs 5274 213 (2.4) 6875 282 (2.4) 0.82 1036 38 (2.1) 1189 36 (1.7) 0.30 
Warfarin 1072 42 (1.9) 1204 59 (2.4) 0.23 1040 40 (1.8) 1185 59 (2.4) 0.17 
Warfarin vs. Antiplatelet drugs, 
HR (95% CI) 
0.77 (0.55, 1.07) 1.00 (0.76, 1.33) 0.23 1.00 (0.42, 2.40) 1.58 (0.77, 3.26) 0.43 
Abbreviations: HR, hazard ratio; CI, confidence interval. 
*Incidence per 100 patient years. 
†Least squares means method was used to compare the incidence of outcome events by gender under Poisson distribution, whereas t-test was used to compare the hazard ratios by 
gender. 
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Table VI. Sensitivity analysis using 180-day permissible medication gap. 
    Overall cohort PS-matched cohort 
  N 
No. of events 
/absolute risk 
/incidence† 
Warfarin vs. 
Antiplatelet drugs, 
HR (95%CI) 
Good vs. Poor 
INR control, 
HR (95%CI) 
N 
No. of events 
/absolute risk 
/incidence† 
Warfarin vs. 
Antiplatelet drugs, 
HR (95%CI) 
Good vs. Poor 
INR control, 
HR (95%CI) 
Ischemic stroke 
        
Antiplatelet drugs 12149 789/6.5/3.7 Reference  2231 135/6.1/3.2 Reference  
Warfarin 2286 78/3.4/1.6 0.44 (0.35, 0.55)*  2231 76/3.4/1.6 0.42 (0.29, 0.59)*  
  Poor INR control 1546 61/3.9/1.9 0.52 (0.40, 0.67)* Reference 1509 59/3.9/1.9 0.50 (0.33, 0.76)* Reference 
  Good INR control 740 17/2.3/1.1 0.29 (0.18, 0.46)* 0.56 (0.33, 0.95)* 722 17/2.4/1.1 0.29 (0.15, 0.54)* 0.58 (0.34, 0.99)* 
  
 
       
Intracranial hemorrhage 
 
       
Antiplatelet drugs 12149 184/1.5/0.9 Reference  2231 31/1.4/0.7 Reference  
Warfarin 2286 42/1.8/0.9 1.01 (0.72, 1.41)  2231 42/1.9/0.9 0.96 (0.56, 1.67)  
  Poor INR control 1546 29/1.9/0.9 1.05 (0.71, 1.55) Reference 1509 29/1.9/0.9 0.94 (0.49, 1.83) Reference 
  Good INR control 740 13/1.8/0.8 0.93 (0.53, 1.64) 0.89 (0.46, 1.71) 722 13/1.8/0.8 1.00 (0.38, 2.66) 0.89 (0.46, 1.71) 
  
 
       
Gastrointestinal bleeding        
Antiplatelet drugs 12149 519/4.3/2.4 Reference  2231 81/3.6/1.9 Reference  
Warfarin 2286 102/4.5/2.1 0.87 (0.70, 1.08)  2231 100/4.5/2.1 0.98 (0.68, 1.42)  
  Poor INR control 1546 66/4.3/2.1 0.85 (0.66, 1.09) Reference 1509 64/4.2/2.0 1.19 (0.74, 1.90) Reference 
  Good INR control 740 36/4.9/2.2 0.92 (0.66, 1.29) 1.08 (0.72, 1.62) 722 36/5.0/2.3 0.73 (0.40, 1.32) 1.11 (0.74, 1.68) 
  
 
       
All-cause mortality 
 
       
Antiplatelet drugs 12149 2677/22.0/12.5 Reference  2231 347/15.6/8.3 Reference  
Warfarin 2286 194/8.5/4.0 0.33 (0.29, 0.38)*  2231 190/8.5/4.0 0.40 (0.31, 0.50)*  
  Poor INR control 1546 135/8.7/4.2 0.34 (0.29, 0.41)* Reference 1509 132/8.7/4.2 0.43 (0.32, 0.56)* Reference 
  Good INR control 740 59/8.0/3.7 0.30 (0.23, 0.39)* 0.87 (0.64, 1.18) 722 58/8.0/3.7 0.33 (0.22, 0.51)* 0.87 (0.64, 1.19) 
Abbreviations: PS, propensity score; HR, hazard ratio; CI, confidence interval; INR, international normalized ratio. 
Poor INR control, time in therapeutic range<60%; Good INR control, time in therapeutic range≥60%.*P Value<0.05. 
†absolute risk per 100 patients; incidence per 100 patient-years. 
 
 
- 17 - 
 
Table VII. Sensitivity analysis using 30-day permissible medication gap. 
  
 
Overall cohort PS-matched cohort 
  N 
No. of events 
/absolute risk 
/incidence† 
Warfarin vs. 
Antiplatelet drugs, 
HR (95%CI) 
Good INR vs. 
Poor INR control, 
HR (95%CI) 
N 
No. of events 
/absolute risk 
/incidence† 
Warfarin vs. 
Antiplatelet drugs, 
HR (95%CI) 
Good INR vs. 
Poor INR control, 
HR (95%CI) 
Ischemic stroke 
        
Antiplatelet drugs 12149 711/5.9/3.8 Reference  2165 111/5.1/3.1 Reference  
Warfarin 2214 66/3.0/1.5 0.40 (0.31, 0.51)*  2165 63/2.9/1.5 0.48 (0.32, 0.72)*  
  Poor INR control 1493 54/3.6/1.8 0.49 (0.37, 0.64)* Reference 1466 51/3.5/1.8 0.60 (0.37, 0.95)* Reference 
  Good INR control 721 12/1.7/0.8 0.21 (0.12, 0.38)* 0.44 (0.23, 0.81)* 699 12/1.7/0.8 0.27 (0.12, 0.62)* 0.47 (0.25, 0.88)* 
          
Intracranial hemorrhage 
 
       
Antiplatelet drugs 12149 159/1.3/0.8 Reference  2165 19/0.9/0.5 Reference  
Warfarin 2214 39/1.8/0.9 1.04 (0.73, 1.48)  2165 39/1.8/0.9 1.80 (0.83, 3.90)  
  Poor INR control 1493 27/1.8/0.9 1.09 (0.72, 1.63) Reference 1466 27/1.8/0.9 1.63 (0.67, 3.92) Reference 
  Good INR control 721 12/1.7/0.8 0.95 (0.53, 1.71) 0.87 (0.44, 1.72) 699 12/1.7/0.8 2.50 (0.49, 12.89) 0.88 (0.45, 1.74) 
  
 
       
Gastrointestinal bleeding         
Antiplatelet drugs 12149 460/3.8/2.4 Reference  2165 55/2.5/1.5 Reference  
Warfarin 2214 93/4.2/2.1 0.86 (0.69, 1.07)  2165 92/4.2/2.1 1.29 (0.84, 1.97)  
  Poor INR control 1493 57/3.8/2.0 0.79 (0.60, 1.05) Reference 1466 56/3.8/1.9 1.29 (0.76, 2.20) Reference 
  Good INR control 721 36/5.0/2.4 0.99 (0.70, 1.38) 1.24 (0.82, 1.88) 699 36/5.2/2.5 1.29 (0.64, 2.59) 1.27 (0.84, 1.94) 
          
All-cause mortality 
 
       
Antiplatelet drugs 12149 2238/18.4/11.9 Reference  2165 281/13.0/7.7 Reference  
Warfarin 2214 150/6.8/3.4 0.29 (0.25, 0.35)*  2165 146/6.7/3.4 0.35 (0.27, 0.46)*  
  Poor INR control 1493 101/6.8/3.5 0.30 (0.24, 0.36)* Reference 1466 99/6.8/3.4 0.32 (0.23, 0.45)* Reference 
  Good INR control 721 49/6.8/3.3 0.29 (0.22, 0.38)* 0.95 (0.68, 1.34) 699 47/6.7/3.3 0.41 (0.27, 0.63)* 0.94 (0.67, 1.33) 
Abbreviations: PS, propensity score; HR, hazard ratio; CI, confidence interval; INR, international normalized ratio. 
Poor INR control, time in therapeutic range<60%; Good INR control, time in therapeutic range≥60%.*P Value<0.05. 
†absolute risk per 100 patients; incidence per 100 patient-years. 
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Table VIII. Baseline characteristics of the patients in the analysis based on CHADS2 score. 
Characteristics Before PS matching After PS matching 
 
Antiplatelet drugs 
(n=7568) 
Warfarin 
(n=1342) 
Standardized 
difference* 
Antiplatelet drugs 
(n=1311) 
Warfarin 
(n=1311) 
Standardized 
difference* 
Age (years), mean ± SD 82.0 ± 8.5 75.4 ± 9.7 -0.73 75.7 ± 10.4 75.9 ± 9.2 0.01 
Age >=65 7223 (95.4) 1128 (84.1) -0.38 1092 (83.3) 1123 (85.7) 0.07 
Age >=75 6547 (86.5) 886 (66.0) -0.50 861 (65.7) 884 (67.4) 0.04 
Sex (Female) 4363 (57.7) 652 (48.6) -0.18 647 (49.4) 645 (49.2) -0.003 
Baseline medical conditions 
   
   
  Congestive heart failure 3702 (48.9) 634 (47.2) -0.03 601 (45.8) 620 (47.3) 0.03 
  Diabetes 2731 (36.1) 566 (42.2) 0.13 579 (44.2) 556 (42.4) -0.04 
  Hypertension 5963 (78.8) 1032 (76.9) -0.05 1040 (79.3) 1018 (77.7) -0.04 
  Myocardial infaraction 1028 (13.6) 101 (7.5) -0.20 92 (7.0) 100 (7.6) 0.02 
  Vascular disease 2762 (36.5) 391 (29.1) -0.16 381 (29.1) 387 (29.5) 0.01 
  Prior transient ischemic attack/systemic embolism 251 (3.3) 167 (12.4) 0.34 117 (8.9) 145 (11.1) 0.07 
  Prior bleeding 664 (8.8) 110 (8.2) -0.02 121 (9.2) 108 (8.2) -0.04 
  Renal disease 1455 (19.2) 190 (14.2) -0.14 201 (15.3) 189 (14.4) -0.03 
  CHA2DS2-VASc score, mean ± SD 4.5 ± 1.1 4.2 ± 1.2 -0.24 4.1 ± 1.2 4.2 ± 1.2 0.06 
    2 122 (1.6) 73 (5.4) 0.21 85 (6.5) 61 (4.7) -0.08 
    3 1357 (17.9) 319 (23.8) 0.14 324 (24.7) 310 (23.6) -0.02 
    ≥4 6089 (80.5) 950 (70.8) -0.23 902 (68.8) 940 (71.7) 0.06 
  CHADS2 score, mean ± SD 2.6 ± 0.7 2.6 ± 0.8 0.004 2.5 ± 0.8 2.6 ± 0.8 0.05 
    2 4172 (55.1) 765 (57.0) 0.04 790 (60.3) 746 (56.9) -0.07 
    3 2572 (34.0) 414 (30.8) -0.07 380 (29.0) 410 (31.3) 0.05 
    ≥4 824 (10.9) 163 (12.1) 0.04 141 (10.8) 155 (11.8) 0.03 
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Table VIII. Baseline characteristics of the patients in the analysis based on CHADS2 score [continued]. 
Characteristics Before PS matching After PS matching 
 
Antiplatelet drugs 
(n=7568) 
Warfarin 
(n=1342) 
Standardized 
difference* 
Antiplatelet drugs 
(n=1311) 
Warfarin 
(n=1311) 
Standardized 
difference* 
Charlson comorbidity index, mean ± SD 2.0 ± 1.8 1.7 ± 1.5 -0.19 1.7 ± 1.4 1.7 ± 1.4 0.02 
  0-3 6348 (83.9) 1195 (89.0) 0.15 1169 (89.2) 1167 (89.0) -0.005 
  4-5 828 (10.9) 114 (8.5) -0.08 108 (8.2) 113 (8.6) 0.01 
  6-7 248 (3.3) 26 (1.9) -0.08 28 (2.1) 26 (2.0) -0.01 
  ≥8 144 (1.9) 7 (0.5) -0.13 6 (0.5) 5 (0.4) -0.01 
Recent use of medications 
   
   
  Aspirin 5310 (70.2) 776 (57.8) -0.26 751 (57.3) 763 (58.2) 0.02 
  Clopidogrel 565 (7.5) 72 (5.4) -0.09 64 (4.9) 71 (5.4) 0.02 
  Amiodarone 1048 (13.8) 145 (10.8) -0.09 126 (9.6) 140 (10.7) 0.04 
  Statin 2213 (29.2) 519 (38.7) 0.20 501 (38.2) 501 (38.2) <.001 
  Proton-pump inhibitor 1686 (22.3) 239 (17.8) -0.11 245 (18.7) 236 (18.0) -0.02 
  Histamine type-2 receptor antagonist 3824 (50.5) 640 (47.7) -0.06 616 (47.0) 626 (47.7) 0.02 
  NSAIDs 472 (6.2) 78 (5.8) -0.02 66 (5.0) 75 (5.7) 0.03 
  SSRIs 163 (2.2) 24 (1.8) -0.03 21 (1.6) 24 (1.8) 0.02 
Anticoagulation control (for warfarin users only)       
  Total number of INR tests included  19517   19013  
  Number of INR tests performed for each   
    patient, mean ± SD 
 15 ± 11   15 ± 11  
  Time in therapeutic range, mean ± SD 
 
42.9 ± 29.0% 
  
 42.7 ± 29.0%  
     <30% 
 
483 (36.0) 
 
 474 (36.2)  
     30-40% 
 
157 (11.7) 
 
 151 (11.5)  
     40-50% 
 
157 (11.7) 
 
 156 (11.9)  
     50-60% 
 
146 (10.9) 
 
 142 (10.8)  
     60-70% 
 
131 (9.8) 
 
 129 (9.8)  
     ≥70% 
 
268 (20.0) 
 
 259 (19.8)  
Abbreviations: PS, propensity score; SD, standard deviation; NSAIDs, nonsteroidal anti-inflammatory drugs; SSRIs, selective serotonin reuptake inhibitors, INR, international normalized ratio. 
*Standardized difference is the mean difference divided by the pooled standard deviation. 
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Table IX. Sensitivity analysis among the high-risk patients taking antiplatelet drugs and warfarin based on CHADS2 score. 
  
 
Overall cohort PS-matched cohort 
  N 
No. of events 
/absolute risk 
/incidence† 
Warfarin vs. 
Antiplatelet drugs, 
HR (95%CI) 
Good vs. Poor 
INR control, 
HR (95%CI) 
N 
No. of events 
/absolute risk 
/incidence† 
Warfarin vs. 
Antiplatelet drugs, 
HR (95%CI) 
Good vs. Poor 
INR control, 
HR (95%CI) 
Ischemic stroke 
        
Antiplatelet drugs 7568 534/7.1/4.3 Reference - 1311 93/7.1/3.9 Reference - 
Warfarin 1342 49/3.7/1.8 0.42 (0.32, 0.57)* - 1311 48/3.7/1.8 0.63 (0.42, 0.95)* - 
    Poor INR control 943 39/4.1/2.1 0.49 (0.35, 0.68)* Reference 923 39/4.2/2.1 0.76 (0.47, 1.24) Reference 
    Good INR control 399 10/2.5/1.2 0.28 (0.15, 0.51)* 0.57 (0.28, 1.13) 388 9/2.3/1.1 0.41 (0.19, 0.89)* 0.51 (0.25, 1.05) 
  
        
Intracranial hemorrhage 
       
- 
Antiplatelet drugs 7568 117/1.5/0.9 Reference - 1311 17/1.3/0.7 Reference - 
Warfarin 1342 31/2.3/1.1 1.21 (0.81, 1.79) - 1311 31/2.4/1.2 1.08 (0.51, 2.29) 
 
    Poor INR control 943 20/2.1/1.1 1.14 (0.71, 1.82) Reference 923 20/2.2/1.1 1.00 (0.38, 2.66) Reference 
    Good INR control 399 11/2.8/1.3 1.36 (0.73, 2.53) 1.18 (0.56, 2.46) 388 11/2.8/1.3 1.20 (0.37, 3.93) 1.17 (0.56, 2.44) 
  
        
Gastrointestinal bleeding         
Antiplatelet drugs 7568 368/4.9/2.9 Reference - 1311 48/3.7/2.0 Reference - 
Warfarin 1342 65/4.8/2.4 0.81 (0.62, 1.05) - 1311 63/4.8/2.4 1.06 (0.66, 1.69) - 
    Poor INR control 943 47/5.0/2.5 0.85 (0.63, 1.16) Reference 923 46/5.0/2.5 1.22 (0.70, 2.11) Reference 
    Good INR control 399 18/4.5/2.1 0.71 (0.45, 1.15) 0.83 (0.48, 1.43) 388 17/4.4/2.0 0.73 (0.29, 1.81) 0.80 (0.46, 1.39) 
  
        
All-cause mortality 
        
Antiplatelet drugs 7568 1891/25.0/15.1 Reference - 1311 197/15.0/8.2 Reference - 
Warfarin 1342 118/8.8/4.3 0.29 (0.24, 0.35)* - 1311 115/8.8/4.3 0.39 (0.29, 0.53)* - 
    Poor INR control 943 80/8.5/4.3 0.29 (0.23, 0.36)* Reference 923 78/8.5/4.3 0.39 (0.28, 0.56)* Reference 
    Good INR control 399 38/9.5/4.4 0.30 (0.22, 0.42)* 1.03 (0.70, 1.52) 388 37/9.5/4.4 0.39 (0.23, 0.68)* 1.02 (0.69, 1.51) 
Abbreviations: PS, propensity score; HR, hazard ratio; CI, confidence interval; INR, international normalized ratio. 
Poor INR control, time in therapeutic range<60%; Good INR control, time in therapeutic range≥60%. *P Value<0.05. 
†absolute risk per 100 patients; incidence per 100 patient-years. 
 
